ReCell Spray-On Skin Revolutionizes Burn Treatment in 30+ Global Centres

Avita Medical's ReCell spray-on skin technology is now in use at over 30 verified burn centres worldwide. The system, designed to regenerate large areas of skin from tiny tissue samples, has seen rapid adoption—especially in the US, where the company targets 120 burn centres and 50-60 top trauma units. Recent clinical trials highlight its effectiveness, particularly for children with severe burns. The company's growth follows regulatory approvals in the US, Australia, and Europe. Hospitals have increasingly adopted ReCell, with procedure volumes rising by more than 50% year-on-year. Strategic partnerships with leading burn centres have further accelerated its integration into routine care, while testing in German clinics signals expanding European interest.

ReCell's success stems from its ability to treat burns with minimal donor skin, reducing scarring and recovery time. Recent data confirms its advantages over traditional methods, especially for paediatric patients. Beyond burns, Avita Medical is now exploring applications for acute wounds and vitiligo, broadening its market potential. Despite progress, challenges remain. Regulatory hurdles and funding dependence pose risks, while the company focuses on scaling production and cutting costs. Limited competition in spray-on skin technology has also drawn attention from potential pharmaceutical acquirers, adding to investor appeal.

Avita Medical's expansion continues, with ReCell now a standard treatment in key burn centres across multiple regions. The company's push into new medical areas and efforts to improve profitability could shape its future trajectory. For investors, its accessible stock and specialised technology offer a distinct opportunity in regenerative medicine.